참고문헌
- Chan PP, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int 2020;19:541-6. https://doi.org/10.1016/j.hbpd.2020.06.013
- Itakura J, Kurosaki M, Kakizaki S, et al. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Rep 2020;2:100138.
- Yun H, Zhao G, Sun X, Shi L. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. BMJ Open 2020;10:e035224.
- Tarr AW, Khera T, Hueging K, et al. Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design. Viruses 2015;7:3995-4046. https://doi.org/10.3390/v7072809
- Grebely J, Prins M, Hellard M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408-14. https://doi.org/10.1016/S1473-3099(12)70010-5
- Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012;209:61-75. https://doi.org/10.1084/jem.20100388
- Filskov J, Andersen P, Agger EM, Bukh J. HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. Sci Rep 2019;9:14085.
- Bailey JR, Dowd KA, Snider AE, et al. CD4+ T-cell-dependent reduction in hepatitis C virus-specific neutralizing antibody responses after coinfection with human immunodeficiency virus. J Infect Dis 2015;212:914-23. https://doi.org/10.1093/infdis/jiv139
- Ahrends T, Busselaar J, Severson TM, et al. CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities. Nat Commun 2019;10:5531.
- Hobernik D, Bros M. DNA vaccines: how far from clinical use? Int J Mol Sci 2018;19:3605.
- Braathen R, Spang HC, Lindeberg MM, et al. The magnitude and IgG subclass of antibodies elicited by targeted DNA vaccines are influenced by specificity for APC surface molecules. Immunohorizons 2018;2:38-53. https://doi.org/10.4049/immunohorizons.1700038
- Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008;29:352-61. https://doi.org/10.1016/j.immuni.2008.09.002
- Keck Z, Wang W, Wang Y, et al. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol 2013;87:37-51. https://doi.org/10.1128/JVI.01941-12
- Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 2014;105:100-11. https://doi.org/10.1016/j.antiviral.2014.02.013
- Bolcic F, Sede M, Moretti F, et al. Analysis of the PKR-eI-F2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Arch Virol 2012;157:703-11. https://doi.org/10.1007/s00705-012-1230-1
- Forns X, Payette PJ, Ma X, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000;32:618-25. https://doi.org/10.1053/jhep.2000.9877
- Alvarez-Lajonchere L, Shoukry NH, Gra B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009;16:156-67. https://doi.org/10.1111/j.1365-2893.2008.01058.x
- Masavuli MG, Wijesundara DK, Underwood A, et al. A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice. Front Immunol 2019;10:1145.
- Alemu EY, Carl JW Jr, Corrada Bravo H, Hannenhalli S. Determinants of expression variability. Nucleic Acids Res 2014;42:3503-14. https://doi.org/10.1093/nar/gkt1364
- Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current challenges in vaccinology. Front Immunol 2020;11:1181.
- Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003;9:68-75.
- De Winter JC. Using the Student's t-test with extremely small sample sizes. Pract Assess Res Eval 2013;18:10.
- Meunier JC, Russell RS, Goossens V, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008;82:966-73. https://doi.org/10.1128/JVI.01872-07
- Morin TJ, Broering TJ, Leav BA, et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012;8:e1002895.
- Keck ZY, Angus AG, Wang W, et al. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog 2014;10:e1004297.
- Keck ZY, Saha A, Xia J, et al. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol 2011;85:10451-63. https://doi.org/10.1128/JVI.05259-11
- Owsianka AM, Timms JM, Tarr AW, et al. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 2006;80:8695-704. https://doi.org/10.1128/JVI.00271-06
- Buccitelli C, Selbach M. mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet 2020;21:630-44. https://doi.org/10.1038/s41576-020-0258-4
- Franco LH, Wowk PF, Silva CL, et al. A DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells. Genet Vaccines Ther 2008;6:3.
- Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259-93. https://doi.org/10.1146/annurev.iy.12.040194.001355
- Sadegh-Nasseri S, Kim A. Selection of immunodominant epitopes during antigen processing is hierarchical. Mol Immunol 2019;113:115-9. https://doi.org/10.1016/j.molimm.2018.08.011
- Ascough S, Ingram RJ, Chu KK, et al. CD4+ T cells targeting dominant and cryptic epitopes from Bacillus anthracis lethal factor. Front Microbiol 2016;6:1506.
- Dai G, Steede NK, Landry SJ. Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120. J Biol Chem 2001;276:41913-20. https://doi.org/10.1074/jbc.M106018200
- Sandberg JK, Glas R. Antigen processing. Hoboken (NJ): Encyclopedia of Life Science/John Wiley & Sons; 2001.
- Chang S, Kodys K, Szabo G. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology 2010;51:35-42. https://doi.org/10.1002/hep.23256
- Wang J, Symul L, Yeung J, et al. Circadian clock-dependent and -independent posttranscriptional regulation underlies temporal mRNA accumulation in mouse liver. Proc Natl Acad Sci U S A 2018;115:E1916-25. https://doi.org/10.1073/pnas.1715225115
- Garcia-Arriaza J, Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother 2014;10:2235-44. https://doi.org/10.4161/hv.28974
- Frey SE, Houghton M, Coates S, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28:6367-73. https://doi.org/10.1016/j.vaccine.2010.06.084